The overexpression of YTHDF1 has been widely regarded as a diagnostic and prognostic biomarker in various tumors, particularly in gastric colorectal cancer, prostate cancer, cervical cancer, hepatocellular carcinoma, breast cancer, and non-small-cell lung cancer. This evidence concerns the gene YTHDF1 and hepatocellular carcinoma.